Pharma

This industry exists because chemistry can reliably reproduce, at industrial scale and low cost, molecules that were once available only from nature or in tiny quantities, turning treatments that used to be rare or impossible into medicines available to hundreds of millions of people. India's specific role, generic manufacturing, exists because patent protection is deliberately time-limited, and once it expires, someone has to actually make the now-unprotected medicine cheaply and reliably at scale.

The second reason India specifically has grown into a research and manufacturing outsourcing hub is cost and talent combined: a large base of skilled chemists and clinical researchers, at a fraction of US or European cost, made India a natural place for global pharma companies to send the research (CRO) and manufacturing (CDMO, CMO) work they did not want, or could not afford, to keep entirely in-house.

Pharma manufactures medicines, overwhelmingly generics, for both domestic use and a globally significant export franchise that has earned India the label "pharmacy of the world." A growing, increasingly important second layer sits underneath that finished-medicine story: India's outsourced research and manufacturing ecosystem, CRO, CDMO and CMO, that global pharmaceutical companies increasingly rely on to actually discover, test and produce their drugs.

India's pharma story is a genuine global success wrapped around one uncomfortable dependency: the country excels at finished generic medicines but had let a meaningful share of the underlying chemical ingredient manufacturing drift to China, a gap the last five years of policy have been explicitly trying to close.

Almost the entire commercial logic of India's pharmaceutical export industry traces back to one recurring event: a blockbuster drug's patent, typically lasting around 20 years from filing, eventually expires, and revenue that had been protected from competition suddenly opens up to anyone who can prove bioequivalence and secure regulatory approval, most commonly through an ANDA in the US market.

Indian companies have built their entire competitive advantage around being ready for this moment before it arrives, filing for approval years in advance so they can launch a generic version within days or weeks of a patent expiring. The CRO-CDMO-CMO ecosystem sits earlier in the same logic, the more of a drug's research and manufacturing India can capture *before* that patent cliff even happens, the less the industry depends on generics alone.

Pharmaceuticals are one of India's genuine export success stories. Pharmaceutical exports reached $30.47 billion in FY2024-25, up 9.4% year on year, with India supplying roughly one in five generic medicines used anywhere in the world by volume, and export rank climbing from 7th in 2019 to 3rd by 2025.

The less celebrated side of that trade balance is the import bill for API and other upstream chemical inputs, which is exactly why the government layered a Rs 60,000 crore API-specific push on top of the original Rs 15,000 crore PLI Pharma scheme in December 2025, alongside 27 greenfield Bulk Drug Parks and 13 medical device plants inaugurated to provide shared manufacturing infrastructure for that push.

Generics manufacturers earn on volume and speed to market, racing to launch immediately after a patent cliff and capturing share before the market becomes fully commoditised, since margins compress quickly once many competitors launch the same generic.

CROs earn service fees for running trials and research on a client's behalf, revenue that is contracted and largely independent of whether the resulting drug ever succeeds commercially. CDMO and CMO companies earn a manufacturing (and, for CDMOs, development) service margin, often more stable than branded generics since they are paid regardless of which company ultimately sells the finished, branded product.

Developing a new drug or securing regulatory approval for a generic carries real upfront cost and risk, clinical trials for new drugs especially, but ANDA filing and plant validation for generics too, all before a single unit is sold.

Once approved, ongoing manufacturing cost, API and other raw material inputs particularly, becomes the recurring driver of margin, which is exactly why API import dependence matters so directly to Indian formulation manufacturers' profitability, not just to national self-reliance goals.

Over the next five years, expect continued API and bulk drug capacity build-out backed by the new Rs 60,000 crore push, accelerating CRO and CDMO investment as global pharma keeps outsourcing both research and manufacturing, and deeper Indian investment in biosimilars and peptide manufacturing to capture growth beyond conventional small-molecule generics.

The real test for India's pharma industry is whether it can move up the value chain, from being the world's generics factory to also being a meaningful CRDMO, biosimilar and peptide manufacturing hub, categories with higher margins and less brutal price competition than conventional generics, and where China currently holds a significant lead.